Testing rate fall leaves thousands of Australians at risk of hepatitis C

hepatitis C
Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Credit: Center for the Study of Hepatitis C, The Rockefeller University.

Around 70,000 Australians have been cured of hepatitis C since 2016 when new highly effective medications became available through the Pharmaceutical Benefits Scheme.

But it's estimated up to 170,000 other Australians remain at serious risk from the deadly blood-borne virus, which can cause liver damage, cirrhosis and cancer over a period of years, showing no symptoms until it's too late.

A new study led by Burnet Institute econometrician, Dr. Nick Scott, found that despite a cure becoming available, the national rate of hepatitis C testing has plunged to 2012 levels.

The study, published in the Medical Journal of Australia, also used mathematical modelling to project that a 50 percent increase in testing will be needed for Australia to meet WHO's goal of eliminating hepatitis C as a public health threat by 2030.

"We've been effective at treating people who are already engaged in care or who are easy to reach, but they only account for about a third of people with hepatitis C," Dr. Scott said.

"What we haven't been good at is finding and diagnosing new people, which is why we're seeing treatment numbers start to decline and why the models are projecting that we are not on track to reach the targets.

"Many of the remaining people with hepatitis C may have never been diagnosed or may have been diagnosed a long time ago and either forgotten or not been linked to appropriate care, so the next steps are about finding or re-engaging them and getting them treated."

Dr. Scott said campaigns targeting high-risk groups such as people who inject drugs had been effective in boosting treatment numbers, but there are also many people with hepatitis C who may not identify as high-risk.

"There's a lot of people who may have injected drugs 20 or 30 years ago, and because that activity has long since stopped, they're not connected to services for people who inject drugs and we're not reaching them with our program," Dr. Scott said.

"I don't think we really know how to reach them—it's going to be a major challenge.

"This study also challenges the idea that just because we have a cure, elimination is going to happen. It's not happening, and the fact that we're testing today at 2012 levels is actually quite alarming."

Study senior author, Burnet Deputy Director Professor Margaret Hellard AM, said the EC (Eliminate Hepatitis C) Australia Partnership has a special role to play to ensure that treatment numbers are maintained to stop new hepatitis C infections and hepatitis C related deaths.

"This paper highlights that one of the major challenges for Australia in eliminating hepatitis C is finding people who are infected with hepatitis C and engaging them in testing and care. The EC Australia Partnership is now focusing on this issue," Professor Hellard said.

"Many people don't know their status, many are discouraged from seeking treatment because of stigma, and it's a tragedy that they are missing out on life-saving therapies which are so readily available."

Co-ordinated by Burnet and funded by the Paul Ramsay Foundation, EC Australia is a multi-million dollar targeted national response to the serious decline in the uptake of the new medications to cure C among Australians living with the deadly virus.


Explore further

Latest research shows Australia on track to cure hepatitis C

More information: Nick Scott et al. Australia needs to increase testing to achieve hepatitis C elimination, Medical Journal of Australia (2020). DOI: 10.5694/mja2.50544
Journal information: Medical Journal of Australia

Provided by Burnet Institute
Citation: Testing rate fall leaves thousands of Australians at risk of hepatitis C (2020, March 30) retrieved 1 December 2020 from https://medicalxpress.com/news/2020-03-fall-thousands-australians-hepatitis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments